| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.18▼ | 1.17▼ | 1.17▲ | 1.19▼ | 1.27▼ |
| MA10 | 1.17▼ | 1.17▼ | 1.18▼ | 1.19▼ | 1.42▼ |
| MA20 | 1.18▼ | 1.18▼ | 1.18▼ | 1.26▼ | 1.62▼ |
| MA50 | 1.18▼ | 1.18▼ | 1.23▼ | 1.44▼ | 2.00▼ |
| MA100 | 1.25▼ | 1.39▼ | 1.41▼ | 1.61▼ | 4.65▼ |
| MA200 | 1.40▼ | 1.50▼ | 1.63▼ | 1.78▼ | N/A |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.000▲ | 0.002▲ | 0.005▲ | 0.006▲ | N/A |
| RSI | 46.302▼ | 46.294▼ | 45.039▼ | 35.233▼ | N/A |
| STOCH | 66.667 | 47.009 | 52.545 | 48.798 | 14.399▼ |
| WILL %R | -50.000 | -53.846 | -53.846 | -65.217 | -93.916▼ |
| CCI | -10.606 | -29.678 | -36.207 | -91.210 | -106.206▼ |
|
Sunday, September 15, 2019 08:47 AM
Leap Therapeutics Inc (NASDAQ: LPTX) will present at the IGCL annual global meeting updated Phase 2 data for DKN-01 and paclitaxel in endometrial cancer. Exagen, a company that sells blood tests for ...
|
|
Friday, August 09, 2019 04:11 AM
Leap Therapeutics (NASDAQ:LPTX): Q2 GAAP EPS of -$0.37 beats by $0.05. Cash and cash equivalents of $15.75M.
|
|
Tuesday, August 06, 2019 04:39 AM
CAMBRIDGE, Mass., Aug. 6, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX) today announced that its anti-Dickkopf-1 (DKK1) antibody, DKN-01, in combination with Merck's anti-PD-1 antibody, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 17/10/19 | 1.14 | 1.18 | 1.14 | 1.17 | 99,820 |
| 16/10/19 | 1.18 | 1.22 | 1.13 | 1.19 | 206,800 |
| 15/10/19 | 1.16 | 1.21 | 1.136 | 1.18 | 111,300 |
| 14/10/19 | 1.22 | 1.27 | 1.14 | 1.17 | 130,500 |
| 11/10/19 | 1.16 | 1.24 | 1.159 | 1.22 | 58,800 |
| 10/10/19 | 1.22 | 1.22 | 1.146 | 1.16 | 146,500 |
| 09/10/19 | 1.20 | 1.24 | 1.188 | 1.21 | 54,900 |
| 08/10/19 | 1.17 | 1.22 | 1.12 | 1.20 | 82,200 |
| 07/10/19 | 1.17 | 1.20 | 1.10 | 1.19 | 91,300 |
| 04/10/19 | 1.22 | 1.24 | 1.1621 | 1.19 | 56,201 |
|
|
||||
|
|
||||
|
|